High-throughput single cell CO-assay of histone modifications andtranscriptome
Ended Project Grant Awarded Last action
- Award ID
- R44GM146330
- Recipient
-
Epigenome Technologies, Inc. UEI LS7JQN77JKQ1
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,091,335
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Disruption of gene regulation is a major causal factor in heritable disease, developmental disorders, and oncogenesis. While chromatin immunoprecipitation followed by sequencing (CHIP-SEQ) and TN5- transposase based tagging (cut & tag) enable analysis of transcription factor binding and epigenetic state profiling in bulk tissue samples and tumor biopsies, they produce only population average signals. Yet regulatory networks and perturbations are heterogeneous between cell classes and types. Single-cell technologies can overcome the challenge of cellular heterogeneity and provide deeper insight into cell type-specific gene regulatory programs in healthy, diseased, and cancerous tissues. In prior work, we developed a single-cell joint assay of histone modification and RNA expression (PAIRED-tag), enabling cell-type-stratified epigenetic profiling from bulk samples. This technology has attracted customers in both academic and nonprofit research. In the proposed study, we will develop automated protocols and effect laboratory informatics systems to establish a PAIRED-tag services laboratory, we will refine our protocol to improve experimental throughput and reduce cost, and we will develop a PAIRED-tag "TF" protocol for profiling transcription factor binding profiles. If successful, the research would enable next- generation multi-omic analysis of tumor or disease samples at comparable cost to single-omic technologies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $825,111 | |
| Amendment | $1,133,112 | |
| Original award | $1,133,112 |
Quick answers
Who received award R44GM146330?
R44GM146330 was awarded to Epigenome Technologies, Inc. by National Institute of General Medical Sciences (National Institutes of Health) on July 3, 2023.
How much is award R44GM146330 worth?
$3,091,335 has been obligated on R44GM146330.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award